Yes, weight loss injections are available on the NHS, but access is significantly more restricted than the licensing criteria suggest, and it's being rolled out in phases that will continue for several years. There are three main NHS routes: GP primary care prescribing of Mounjaro (currently limited to a high-need cohort with a BMI of 40+ and multiple health conditions), specialist Tier 3 weight management services (BMI 35+, or 30+ for some ethnic groups, plus one weight-related condition, but often with long waiting lists), and a new, narrower pathway allowing GPs to prescribe Wegovy directly to patients with a BMI of 27+ and existing cardiovascular disease. Private treatment through a GPhC-registered pharmacy is available immediately to anyone meeting the standard licensing criteria — a BMI of 30+, or 27+ with a weight-related condition — without needing to wait for your NHS cohort to open.
The confusion around NHS eligibility mostly comes down to the fact that there isn't one single pathway — there are three, each with different criteria, different waiting times, and different medicines available through them.
Route 1: GP Primary Care Prescribing (Mounjaro Only)
Since 2025, NHS England has allowed some GP practices to prescribe Mounjaro (tirzepatide) directly for weight management, without a specialist referral. This is being rolled out through a phased cohort system designed to prioritise the patients with the greatest clinical need first, given that an estimated 3.4 million adults in England meet the full NICE eligibility criteria — far more than the NHS can accommodate at once.
| Cohort | Criteria | Status |
|---|---|---|
| Cohort 1 | BMI 40+ (37.5+ with ethnic adjustment) and at least 4 of 5 qualifying long-term conditions | Prescribable by participating GPs since June 2025 |
| Cohort 2 | BMI 35+ with fewer qualifying conditions | Expected to widen access from around June 2026 |
| Cohort 3 | Closer to the full NICE recommendation: BMI 35+ (32.5+ adjusted) with 1+ condition | Planned for later in the phased rollout, timeline still developing |
The five qualifying long-term conditions used to define Cohort 1 include type 2 diabetes, hypertension, dyslipidaemia (abnormal blood fats), obstructive sleep apnoea and established cardiovascular disease. Not every GP practice has opted in to prescribe under this scheme yet, so even meeting Cohort 1 criteria doesn't guarantee your own surgery is currently offering it — this varies by local Integrated Care Board (ICB) and by practice.
Route 2: Specialist Weight Management Services (Tier 3)
This is the longer-established NHS route, and it covers a wider range of medicines, including semaglutide (Wegovy), tirzepatide (Mounjaro) and the older daily injection liraglutide (Saxenda). To access it, you're typically referred by your GP to a specialist Tier 3 weight management service, where eligibility is based on NICE's core criteria: a BMI of 35 or above (32.5 or above for South Asian, Chinese, other Asian, Middle Eastern, Black African or Black Caribbean backgrounds, where lower BMI thresholds are used to reflect higher risk at a lower BMI), alongside at least one weight-related health condition.
The practical challenge with this route is capacity. Tier 3 services are in high demand, and waiting times of 18 months or more are commonly reported, varying considerably by region. You'll also usually be expected to take part in a structured programme of dietary and lifestyle support alongside medication, rather than receiving a prescription in isolation.
Route 3: The New Cardiovascular Pathway for Wegovy (April 2026)
From April 2026, NICE introduced a more targeted route that allows GPs to prescribe Wegovy directly, bypassing the Tier 3 referral process entirely, for a specific group of patients: those with a BMI of 27 or above and established cardiovascular disease (a prior heart attack, stroke, transient ischaemic attack, or peripheral arterial disease). This pathway is based on the SELECT trial, in which semaglutide reduced major cardiovascular events by 20% in this population — and reflects a shift towards a more targeted, evidence-based approach to who benefits most, rather than BMI-based criteria alone.
Worth knowing
If you've had a heart attack, stroke or TIA and have a BMI of 27 or above, it's worth asking your GP directly whether you qualify under this specific NICE cardiovascular pathway — it's newer and less widely known than the standard weight management routes, and adoption varies between GP practices.
The clearest way to understand the difference is to compare the criteria and realistic timelines side by side.
| Route | Typical criteria | Realistic timeline |
|---|---|---|
| NHS — GP primary care (Mounjaro, Cohort 1) | BMI 40+ (37.5+ adjusted), 4+ conditions | Immediate if your GP practice participates and you qualify |
| NHS — Tier 3 specialist service | BMI 35+ (32.5+ adjusted), 1+ condition | Often 18+ months from referral |
| NHS — Wegovy cardiovascular pathway | BMI 27+, established cardiovascular disease | Varies by GP practice adoption |
| Private (GPhC-registered pharmacy) | BMI 30+, or 27+ with a weight-related condition | Typically days, following consultation |
This is why so many people who are clinically eligible under NICE's broader guidance end up choosing the private route — not because the NHS won't eventually treat them, but because the phased rollout means their specific cohort or local pathway hasn't opened yet.
Why Is NHS Access So Restricted?It comes down to scale. NICE estimates that around 3.4 million adults in England meet the full clinical criteria for tirzepatide alone, which would represent an enormous and immediate cost and capacity burden if funded all at once. NHS England requested, and was granted, a funding variation that allows the rollout to happen in phases over several years rather than in one step — prioritising the patients considered to have the greatest clinical need first, based on a combination of BMI and the number of weight-related health conditions they have.
Alongside medication, the NHS pathway also requires wraparound support — known as Behavioural Support for Obesity Prescribing (BSOP) — covering nutritional and dietetic advice, delivered as a mandatory part of primary care prescribing. This reflects the same principle used in the drug licensing itself: these medicines are licensed and recommended for use alongside diet and lifestyle support, not as a replacement for it.
| Medicine | NHS primary care | NHS Tier 3 | Private |
|---|---|---|---|
| Mounjaro (tirzepatide) | Yes — phased cohorts | Yes | Yes |
| Wegovy injection (semaglutide) | Yes — cardiovascular pathway only | Yes | Yes |
| Wegovy pill (oral semaglutide) | Not yet on an NHS pathway | Not yet on an NHS pathway | Yes |
| Saxenda (liraglutide) | No | Yes | Limited availability |
The Wegovy pill, approved by the MHRA on 11 June 2026, is currently only available privately — it hasn't yet been through the NICE appraisal and NHS commissioning process required for either primary care or Tier 3 access, which typically takes time to follow after a new medicine's initial licensing.
What If You Don't Qualify for NHS Treatment Yet?If you meet the standard licensing criteria — a BMI of 30 or above, or 27 or above with a weight-related condition — but your NHS cohort hasn't opened, or your local Tier 3 waiting list is long, private treatment through a regulated pharmacy is a legitimate and immediately available option. It uses the same licensed medicines, prescribed by the same category of registered clinicians, following a proper clinical consultation.
Important
Always access weight loss injections through a GPhC-registered pharmacy or another properly regulated route. The MHRA has reported a sharp rise in counterfeit and unlicensed weight loss injections sold online and through social media, some containing incorrect doses or entirely different, potentially dangerous substances. A registered pharmacy will always require a proper clinical consultation before prescribing — any provider willing to skip this step should be treated as a red flag, not a shortcut.
Don't Want to Wait for the NHS Rollout?
If you meet the private eligibility criteria, you don't need to wait for your NHS cohort to open. A free online consultation with our GPhC-registered pharmacy team can get you started safely and quickly.
Start Your Free Online Consultation → Use code SWITCH10 if you're switching from another providerHappy Pharmacy is a GPhC-registered pharmacy (No. 9012585) — Superintendent Pharmacist: Palvinder Deol — Rated 4.8★ Excellent on Trustpilot
- NICE. Technology appraisal guidance TA1026: Tirzepatide for managing overweight and obesity.
- NHS England. Interim commissioning guidance: NICE TA1026 tirzepatide implementation.
- NHS England. Tirzepatide (Mounjaro®) in primary care for weight management: information on wrap-around care. 2026.
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221–2232.
- NICE. Cardiovascular risk reduction prescribing pathway for semaglutide, April 2026.
- MHRA. Oral semaglutide (Wegovy pill) authorisation, 11 June 2026.